Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Summary

The purpose of this study is to determine the effectiveness of fenretinide (4-HPR/LXS) plus ketoconazole in the treatment of recurrent ovarian cancer or primary peritoneal carcinoma. In addition, researchers would like to determine if the drugs are most effective together or if fenretinide (4-HPR/LXS) is most effective alone.

Timeline

Start

2012-02

Primary completion

2017-06

Completion

2017-06

Outcome

Outcome not reported

Stopped: “drug combination not providing any efficacy. Will use this data in opening new trial”

Drugs

Indications